Victor Ling | |
---|---|
Born | 1943 (age 80–81) Shanghai, China |
Nationality | Canadian |
Alma mater | University of Toronto |
Known for | Discovery of P-glycoprotein |
Chinese name | |
Traditional Chinese | 林重慶 |
Hanyu Pinyin | Lín Chóngqìng |
Teochew Peng'im | Lim5 Cong5-kêng3 |
Victor Ling, OC OBC (林重慶; born 1943) is a Canadian researcher in the field of medicine. Ling's research focuses on drug resistance in cancer. He is best known for his discovery of P-glycoprotein, one of the proteins responsible for multidrug resistance.
Ling was born in Shanghai, China in 1943, and is of Teochew ancestry. He moved to Hong Kong with his family in 1949 and lived there until 1952, when they emigrated to Canada. [1] [2] He graduated from North Toronto Collegiate in 1962. He received his bachelor's degree in 1966 from the University of Toronto and his PhD in 1969 from the University of British Columbia.
Ling undertook post-doctoral training with Nobel laureate Fred Sanger at Cambridge University before returning to Toronto. [3] He is currently[ when? ] Assistant Dean of the Faculty of Medicine at the University of British Columbia and former vice-president, Discovery at the BC Cancer Agency in Vancouver, British Columbia, as well as the President and Scientific Director of the Terry Fox Research Institute.
Michael Smith was a British-born Canadian biochemist and businessman. He shared the 1993 Nobel Prize in Chemistry with Kary Mullis for his work in developing site-directed mutagenesis. Following a PhD in 1956 from the University of Manchester, he undertook postdoctoral research with Har Gobind Khorana at the British Columbia Research Council in Vancouver, British Columbia, Canada. Subsequently, Smith worked at the Fisheries Research Board of Canada Laboratory in Vancouver before being appointed a professor of biochemistry in the UBC Faculty of Medicine in 1966. Smith's career included roles as the founding director of the UBC Biotechnology Laboratory and the founding scientific leader of the Protein Engineering Network of Centres of Excellence (PENCE). In 1996 he was named Peter Wall Distinguished Professor of Biotechnology. Subsequently, he became the founding director of the Genome Sequencing Centre at the BC Cancer Research Centre.
Phil Gold is a Canadian physician, scientist, professor and author.
The Gairdner Foundation is a non-profit organization devoted to the recognition of outstanding achievements in biomedical research worldwide. It was created in 1957 by James Arthur Gairdner to recognize and reward the achievements of medical researchers whose work contributes significantly to improving the quality of human life. Since the first awards were made in 1959, the Gairdner Awards have become Canada's most prestigious medical awards, recognizing and celebrating the research of the world’s best and brightest biomedical researchers. Since 1959, more than 390 Canada Gairdner Awards have been given to scientists from 35 countries; of these recipients, 98 have subsequently gone on to win a Nobel Prize.
Anthony James Pawson was a British-born Canadian genetic scientist.
Henry George Friesen is a Canadian endocrinologist, a distinguished professor emeritus of the University of Manitoba and the discoverer of human prolactin, a hormone which stimulates lactation in mammary glands.
Robert Laing Noble was a Canadian physician who was involved in the discovery of vinblastine.
Tak Wah Mak, is a Canadian medical researcher, geneticist, oncologist, and biochemist. He first became widely known for his discovery of the T-cell receptor in 1983 and pioneering work in the genetics of immunology. In 1995, Mak published a landmark paper on the discovery of the function of the immune checkpoint protein CTLA-4, thus opening the path for immunotherapy/checkpoint inhibitors as a means of cancer treatment. Mak is also the founder of Agios Pharmaceuticals, whose lead compound, IDHIFA®, was approved by the FDA for acute myeloid leukemia in August 2017, becoming the first drug specifically targeting cancer metabolism to be used for cancer treatment. He has worked in a variety of areas including biochemistry, immunology, and cancer genetics.
Constance Jean Eaves CorrFRSE was a Canadian biologist with significant contributions to cancer and stem cell research. Eaves was a professor generics of genetics at the University of British Columbia and was also the co-founder with Allen C Eaves of Terry Fox Laboratory.
Nahum Sonenberg, is an Israeli Canadian microbiologist and biochemist. He is a James McGill professor of biochemistry at McGill University in Montreal, Quebec, Canada. He was an HHMI international research scholar from 1997 to 2011 and is now a senior international research scholar. He is best known for his seminal contributions to our understanding of translation, and notable for the discovery of the mRNA 5' cap-binding protein, eIF4E, the rate-limiting component of the eukaryotic translation apparatus.
Alan Bernstein is Professor Emeritus at the University of Toronto and President Emeritus of the Canadian Institute for Advanced Research (CIFAR), where he served as President and CEO from 2012 to 2022. A Distinguished Fellow at the Munk School of Global Affairs and Public Policy, he is also a Fellow and Member of the Standing Committee for Science Planning at the International Science Council (2022-2025). Canadian Bernstein is recognized as a leader in health research, science policy, mentorship and organizational leadership.
Michael R. Hayden, is a Killam Professor of Medical Genetics at the University of British Columbia, the highest honour UBC can confer on any faculty member. Only four such awards have ever been conferred in the Faculty of Medicine. Dr. Hayden is also Canada Research Chair in Human Genetics and Molecular Medicine. Hayden is best known for his research in Huntington disease (HD).
The UBC Faculty of Medicine is the medical school of the University of British Columbia. It is one of 17 medical schools in Canada and the only one in the province of British Columbia. It has Canada's largest undergraduate medical education program and the fifth-largest in the U.S. and Canada. It is ranked as the 2nd best medical program in Canada by Maclean's, and 27th in the world by the 2017 QS World University Rankings.
David Y. H. Lui (CM) was a prominent Canadian arts impresario and producer, highly respected for constructing the arts infrastructure in Vancouver.
Julio S. G. Montaner, is an Argentine-born Canadian physician, professor and researcher. He is the director of the British Columbia Centre for Excellence in HIV/AIDS, the chair in AIDS Research and head of the Division of AIDS in the Faculty of Medicine at the University of British Columbia and the past-president of the International AIDS Society. He is also the director of the John Ruedy Immunodeficiency Clinic, and the Physician Program Director for HIV/AIDS PHC. He is known for his work on HAART, a role in the discovery of triple therapy as an effective treatment for HIV in the late 1990s, and a role in advocating the "Treatment as Prevention" Strategy in the mid-2000s, led by Myron Cohen of the HPTN 052 trial.
Calvin Ralph Stiller is a Canadian physician, scientist, and entrepreneur. He retired as a member of the Schulich School of Medicine & Dentistry at Western University in London, Ontario.
Perry Kendall, is a Canadian Public health physician who was Provincial Health Officer (PHO) for the Canadian province of British Columbia's health ministry from 1999-2018 and was awarded the Order of British Columbia for contributions to Public health field and to harm reduction policy and practice.
Dr. Martin Gleave is a Canadian surgeon and cancer researcher who was appointed to the Order of Canada in 2018.
Lewis Edward Kay, is a Canadian academic and biochemist known for his research in biochemistry and nuclear magnetic resonance spectroscopy for the studies of the structure and behaviour of proteins. He is a professor of molecular genetics, biochemistry and chemistry at the University of Toronto and Senior Scientist in Molecular Medicine at The Hospital for Sick Children.
Pieter Rutter Cullis is a Canadian physicist and biochemist known for his contributions to the field of lipid nanoparticles (LNP). Cullis and co-workers have been responsible for fundamental advances in the development of nanomedicines employing lipid nanoparticle (LNP) technology for cancer therapies, gene therapies and vaccines. This work has contributed to five drugs that have received clinical approval by the US Food and Drug Agency (FDA), the European Medicines Agency, and Health Canada.